Transcriptional regulation in normal and malignant hematopoiesis
The broad interests of the Cantor Laboratory are to elucidate the gene regulatory mechanisms involved in normal blood cell development and to understand how their dysregulation leads to certain human blood disorders. This involves studies of hematopoietic transcription factors, chromatin remodeling complexes, epigenetics, chromatin architecture, signal transduction, stem cell self-renewal, cell fate decisions and terminal cell maturation. Our work pertains to human leukemias, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), congenital dyserythropoieitic anemias/thrombocytopenias, sickle cell disease, and thalassemia.
Our overall aim is to use this new information to develop novel rationally-designed therapies for these blood disorders. We strive to apply cutting-edge technologies to address these problems and currently utilize a variety of approaches including proteomics, genomics, chromatin interaction analysis, gene editing, mouse genetics, human genetics, and human iPS cell technology. We are committed to training the next generation of researchers in this area.
